Larimar Therapeutics Stock Net Asset
| LRMR Stock | USD 3.44 0.02 0.58% |
Fundamental analysis of Larimar Therapeutics allows traders to better anticipate movements in Larimar Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Larimar | Net Asset | Build AI portfolio with Larimar Stock |
Larimar Therapeutics Company Net Asset Analysis
Larimar Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Larimar Therapeutics Net Asset | 200.22 M |
Most of Larimar Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Larimar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Larimar Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Larimar Therapeutics is extremely important. It helps to project a fair market value of Larimar Stock properly, considering its historical fundamentals such as Net Asset. Since Larimar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Larimar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Larimar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Larimar Total Assets
Total Assets |
|
Based on the recorded statements, Larimar Therapeutics has a Net Asset of 200.22 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Larimar Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Larimar Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Larimar Therapeutics could also be used in its relative valuation, which is a method of valuing Larimar Therapeutics by comparing valuation metrics of similar companies.Larimar Therapeutics is currently under evaluation in net asset category among its peers.
Larimar Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Larimar Therapeutics from analyzing Larimar Therapeutics' financial statements. These drivers represent accounts that assess Larimar Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Larimar Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 254.4M | 185.2M | 106.4M | 199.8M | 237.1M | 254.1M | |
| Enterprise Value | 192.8M | 121.1M | 85.0M | 178.5M | 209.0M | 218.6M |
Larimar Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Larimar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Larimar Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Larimar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Larimar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Larimar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Larimar Therapeutics' value.| Shares | State Street Corp | 2025-03-31 | 832.5 K | Mangrove Partners | 2025-03-31 | 770.2 K | Millennium Management Llc | 2025-03-31 | 673 K | Woodline Partners Lp | 2025-03-31 | 622.7 K | Verition Fund Managegment, Llc | 2025-03-31 | 567.7 K | Citadel Advisors Llc | 2025-03-31 | 434.3 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 411.4 K | Two Sigma Investments Llc | 2025-03-31 | 394.7 K | Two Sigma Advisers, Llc | 2025-03-31 | 394 K | Deerfield Management Co | 2025-03-31 | 21.2 M | Ra Capital Management, Llc | 2025-03-31 | 6 M |
Larimar Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 68.88 M | ||||
| Shares Outstanding | 64.03 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 6.15 M | ||||
| Price To Book | 1.54 X | ||||
| EBITDA | (80.29 M) | ||||
| Net Income | (80.6 M) | ||||
| Cash And Equivalents | 54.92 M | ||||
| Cash Per Share | 3.10 X | ||||
| Total Debt | 5.12 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.35 X | ||||
| Book Value Per Share | 2.25 X | ||||
| Cash Flow From Operations | (70.76 M) | ||||
| Short Ratio | 5.35 X | ||||
| Earnings Per Share | (1.51) X | ||||
| Target Price | 20.8 | ||||
| Number Of Employees | 65 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 221.54 M | ||||
| Total Asset | 200.22 M | ||||
| Retained Earnings | (269.16 M) | ||||
| Working Capital | 170.95 M | ||||
| Net Asset | 200.22 M |
About Larimar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Larimar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Larimar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Larimar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Larimar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Larimar Stock
Moving against Larimar Stock
| 0.9 | ERNA | Eterna Therapeutics | PairCorr |
| 0.58 | CLOV | Clover Health Investments Earnings Call This Week | PairCorr |
| 0.54 | TELO | Telomir Pharmaceuticals, | PairCorr |
| 0.45 | MOLN | Molecular Partners | PairCorr |
| 0.34 | LPCN | Lipocine | PairCorr |
The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.